Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a cholesterol drug keep atrial fibrillation at bay after ablation?

NCT ID NCT07752758

Disease control Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This trial tests whether ezetimibe, a common cholesterol-lowering medication, can reduce the return of irregular heartbeats in people with persistent atrial fibrillation who undergo catheter ablation. Half of the 120 participants will take ezetimibe daily for six months after the procedure, while the other half receives standard care. The main goal is to see if ezetimibe lowers the chance of atrial arrhythmia recurrence within six months, potentially offering a simple way to improve long-term outcomes after ablation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ezetimibe, an oral cholesterol-lowering drug, taken as 10 mg once daily for 6 months after catheter ablation.
What this could lead to
If effective, ezetimibe could become a simple, low-cost addition to post-ablation care, potentially reducing the need for repeat procedures and improving long-term heart rhythm control.
What could go wrong
This is a small pilot study, so results may not be conclusive. Ezetimibe is generally well-tolerated but can cause muscle or liver side effects, and its benefit for AF recurrence is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 to 80 years, male or female. 2. Diagnosis of persistent atrial fibrillation (AF) scheduled for first catheter ablation. 3. Able to provide written informed consent. 4. Able to comply with study follow-up and ECG monitoring requirements. Exclusion Criteria: 1. Previous catheter ablation for atrial fibrillation. 2. Life expectancy \<12 months due to non-cardiac comorbidities. 3. Severe valvular heart disease requiring surgery or intervention. 4. Acute myocardial infarction or stroke within the past 3 months. 5. Current participation in another investigational drug/device study. 6. Inability to adhere to study procedures or follow-up. 7. Pregnancy or breastfeeding (female participants).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation Atrial Remodeling persistent atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation Post-catheter ablation atrial arrhythmia recurrence

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.